Stocks and Investing
Stocks and Investing
Tue, November 16, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, November 15, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Graig Suvannavejh Downgraded (TGTX) to Strong Sell and Decreased Target to $26 on, Nov 15th, 2021
Graig Suvannavejh of Goldman Sachs, Downgraded "TG Therapeutics, Inc." (TGTX) to Strong Sell and Decreased Target from $33 to $26 on, Nov 15th, 2021.
Graig has made no other calls on TGTX in the last 4 months.
There is 1 other peer that has a rating on TGTX. Out of the 1 peers that are also analyzing TGTX, 0 agree with Graig's Rating of Hold.
This is the rating of the analyst that currently disagrees with Graig
- Edward White of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $84 on, Monday, August 2nd, 2021
Contributing Sources